Rachel Onifarasoaniaina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rachel Onifarasoaniaina has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Abdelali Jalil
Université Paris Cité, CNRS, Saints-Pères Paris Institute for the Neurosciences, F-75006 Paris, France
2 shared publications Ahmed Hamaï
Université Paris Cité, INSERM, CNRS, Institut Necker Enfants Malades, F-75015, Paris, France
2 shared publications- Alexandre How-Kit
Laboratory for Genomics, Foundation Jean Dausset – CEPH, Paris, France
2 shared publications - Andreea Calugareanu
Dermatology Department Hôpital Emile Muller, GHR Mulhouse Sud Alsace Mulhouse France
2 shared publications - Anne Saussine
Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
2 shared publications - Charles Cassius
Department of Dermatology, Hôpital Saint‐Louis, AP‐HP; INSERM U1342 Université Paris Cité Paris France
2 shared publications
Latest Publications
- Open Access
- 16 September 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (10) , 2652
Author Correction: CBX3 antagonizes IFNγ/STAT1/PD-L1 axis to modulate colon inflammation and CRC chemosensitivity
- 16 September 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (10) , 2652
Open AccessAuthor Correction: CBX3 antagonizes IFNγ/STAT1/PD-L1 axis to modulate colon inflammation and CRC chemosensitivity
- Open Access
- 29 April 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (6) , 1404-1426
CBX3 antagonizes IFNγ/STAT1/PD-L1 axis to modulate colon inflammation and CRC chemosensitivity
As an important immune stimulator and modulator, IFNγ is crucial for gut homeostasis and its dysregulation links to diverse colon pathologies, such as colitis and colorectal cancer (CRC). Here, we demonstrated that the epigenetic regulator, CBX3 (also known as HP1γ) antagonizes IFNγ signaling in the colon epithelium by transcriptionally repressing two critical IFNγ-responsive genes: STAT1 and CD274 (encoding Programmed death-ligand 1, PD-L1). Accordingly, CBX3 deletion resulted in chronic mouse colon inflammation, accompanied by upregulated STAT1 and CD274 expressions. Chromatin immunoprecipitation indicated that CBX3 tethers to STAT1 and CD274 promoters to inhibit their expression. Reversely, IFNγ significantly reduces CBX3 binding to these promoters and primes gene expression. This antagonist effect between CBX3 and IFNγ on STAT1/PD-L1 expression was also observed in CRC. Strikingly, CBX3 deletion heightened CRC cells sensitivity to IFNγ, which ultimately enhanced their chemosensitivity under IFNγ stimulation in vitro with CRC cells and in vivo with a syngeneic mouse tumor model. Overall, this work reveals that by negatively tuning IFNγ-stimulated immune genes’ transcription, CBX3 participates in modulating colon inflammatory response and CRC chemo-resistance.
- 29 April 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (6) , 1404-1426
Open AccessCBX3 antagonizes IFNγ/STAT1/PD-L1 axis to modulate colon inflammation and CRC chemosensitivity
As an important immune stimulator and modulator, IFNγ is crucial for gut homeostasis and its dysregulation links to diverse colon pathologies, such as colitis and colorectal cancer (CRC). Here, we demonstrated that the epigenetic regulator, CBX3 (also known as HP1γ) antagonizes IFNγ signaling in the colon epithelium by transcriptionally repressing two critical IFNγ-responsive genes: STAT1 and CD274 (encoding Programmed death-ligand 1, PD-L1). Accordingly, CBX3 deletion resulted in chronic mouse colon inflammation, accompanied by upregulated STAT1 and CD274 expressions. Chromatin immunoprecipitation indicated that CBX3 tethers to STAT1 and CD274 promoters to inhibit their expression. Reversely, IFNγ significantly reduces CBX3 binding to these promoters and primes gene expression. This antagonist effect between CBX3 and IFNγ on STAT1/PD-L1 expression was also observed in CRC. Strikingly, CBX3 deletion heightened CRC cells sensitivity to IFNγ, which ultimately enhanced their chemosensitivity under IFNγ stimulation in vitro with CRC cells and in vivo with a syngeneic mouse tumor model. Overall, this work reveals that by negatively tuning IFNγ-stimulated immune genes’ transcription, CBX3 participates in modulating colon inflammatory response and CRC chemo-resistance.
- 30 May 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (12) , 2525-2529.e5
Transcriptomic Landscape of Prurigo Nodularis Lesional Skin CD3+ T Cells Using Single-Cell RNA Sequencing
- 30 May 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (12) , 2525-2529.e5
Transcriptomic Landscape of Prurigo Nodularis Lesional Skin CD3+ T Cells Using Single-Cell RNA Sequencing
- 5 January 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (5) , 711-721.e7
IL-4/IL-13 Inhibitors for Atopic Dermatitis Induce Psoriatic Rash Transcriptionally Close to Pustular Psoriasis
- 5 January 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (5) , 711-721.e7
IL-4/IL-13 Inhibitors for Atopic Dermatitis Induce Psoriatic Rash Transcriptionally Close to Pustular Psoriasis